Replies to post #209470 on Amarin Corp Plc (AMRN)

[Biobillionair]

JL-I also agree, the value of Vascepa is beyond imagination. I also think that delaying the approval is an overreaction to Novartis data scandal. I know that further labeling delays will lead to increased cardiovascular deaths and events; this is unacceptable. What can be done about this?
BB